EGFR and non-small cell lung carcinoma: Approximately, 12–15% of non-squamous non-small cell lung cancers (NSCLC) are molecularly characterized by an activating mutation in the epidermal growth factor receptor (EGFR) (Cancer Genome Atlas Research 2014; Rosell et al. 2009; Zhang et al. 2016).